All Stories

  1. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study)

    Article • Current Neuropharmacology, June 2024, Bentham Science Publishers

    Dr Emanuele D'amico

  2. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience

    Article • Current Neuropharmacology, February 2024, Bentham Science Publishers

    Dr Emanuele D'amico

  3. An update on the safety of treating relapsing-remitting multiple sclerosis

    Article • Expert Opinion on Drug Safety, August 2019, Taylor & Francis

    Dr Emanuele D'amico

  4. New treatment targets in multiple sclerosis therapy

    Article • Expert Review of Precision Medicine and Drug Development, June 2019, Taylor & Francis

    Dr Emanuele D'amico

  5. Pharmacoeconomics of synthetic therapies for multiple sclerosis

    Article • Expert Opinion on Pharmacotherapy, May 2019, Taylor & Francis

    Dr Emanuele D'amico

  6. Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support

    Article • Disability and Rehabilitation, May 2019, Taylor & Francis

    Dr Emanuele D'amico , Antonella Delle Fave

  7. Management of dysphagia in multiple sclerosis: current best practice

    Article • Expert Review of Gastroenterology & Hepatology, November 2018, Taylor & Francis

    Dr Emanuele D'amico

  8. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis

    Article • European Journal of Neurology, September 2018, Wiley

    Dr Emanuele D'amico , Professor Ivan G. Milanov

  9. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study

    Article • European Journal of Neurology, August 2018, Wiley

    Dr Emanuele D'amico

  10. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience

    Article • Expert Review of Clinical Pharmacology, March 2018, Taylor & Francis

    Dr Emanuele D'amico

  11. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience

    Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

    Dr Emanuele D'amico

  12. To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

    Article • Expert Review of Neurotherapeutics, June 2017, Taylor & Francis

    Professor Tjalf Ziemssen, Dr Emanuele D'amico

  13. Prognostic indicators in pediatric clinically isolated syndrome

    Article • Annals of Neurology, May 2017, Wiley

    Dr Tim Spelman, Dr Roberto Bergamaschi, Dr Emanuele D'amico

  14. Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal

    Article • Multiple Sclerosis Journal, February 2016, SAGE Publications

    Dr Emanuele D'amico

  15. Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives

    Article • Expert Review of Neurotherapeutics, February 2015, Taylor & Francis

    Dr Emanuele D'amico

  16. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

    Article • Patient Preference and Adherence, January 2010, Taylor & Francis

    Dr Emanuele D'amico

  17. Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab

    Article • ClinicoEconomics and Outcomes Research, August 2009, Taylor & Francis

    Dr Emanuele D'amico